Aspects of platelet disturbances in haemodialysis patients

Clinical Kidney Journal

Volumn 6, Issue 3, 2013, Pages 266-271

  Schoorl, Marianne ^a   Grooteman, Muriel P C ^b   Bartels, Piet C M ^a   Nubé, Menso J ^b  

^a Location Alkmaar   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

coagulation; end stage kidney disease; extracorporeal blood circulation; platelet activation

Indexed keywords

BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7A; CITRATE TRISODIUM; CUPROPHANE; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; POLYACRYLONITRILE; THROMBIN;

BIOCOMPATIBILITY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CARDIOVASCULAR RISK; DEGRANULATION; DIALYSIS MEMBRANE; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRINOLYSIS; HEMODIALYSIS; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE DISORDER; THROMBOCYTOPOIESIS; THROMBOSIS; VASCULAR ACCESS;

EID: 84878527978     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sft033     Document Type: Review

References (29)

1. Adams MJ, Irish AB, Watts GF et al. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res 2008; 123: 374-380
2. Kushiya F, Wada H, Sakakura M et al. Atherosclerotic and he-mostatic abnormalities in patients undergoing hemodialysis. Clin Appl Thromb Hemost 2003; 9: 53-60
3. Undas A, Kolarz M, Kopec G et al. Altered fibrin clot properties in patients on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 2008; 23: 2010-2015
4. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost 2004; 30: 579-589
5. Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial 2006; 19: 317-322
6. Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Semin Dial 2009; 22: 279-286
7. Lohr JW, Schwab SJ. Minimizing hemorrhagic complications in dialysis patients. J Am Soc Nephrol 1991; 2: 961-975
8. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494
9. Bartels PCM, Schoorl M, Schoorl M et al. Activation of coagulation during treatment with haemodialysis. Scand J Clin Lab Invest 2000; 60: 283-290
10. Bartels PC, Schoorl M, Schoorl M et al. Deviations in coagulation activation due to treatment with different haemodia-lysis membranes. Scand J Clin Lab Invest 2003; 63: 417-424
11. Bartels PCM, Schoorl M, Schoorl M. Activatie van stolling tijdens hemodialyse is afhankelijk van de wijze van antistol-ling [Activation of coagulation during haemodialysis is dependent on the type of anti-coagulant]. Ned Tijdschr Klin Chem Labgeneesk 2005; 30: 282-284
12. Schoorl M, Schoorl M, Bartels PC. Changes in platelet volume, morphology and RNA content in subjects treated with hae-modialysis. Scand J Clin Lab Invest 2008; 68: 335-342
13. De Sanctis LB, Stefoni S, Cianciolo G et al. Effect of different dialysis membranes on platelet function. A tool for biocom-patibility evaluation. Int J Artif Organs 1996; 19: 404-410
14. Lang T, Depka von M. Possibilities and limitations of throm-boelastometry/thromboelastography. Hämostaseologie 2006; 26: S21-S29
15. Schoorl M, Schoorl M, Nub MJ et al. Platelet depletion, platelet activation and coagulation during treatment with hemo-dialysis. Scand J Clin Lab Invest 2011; 71: 240-247
16. Opatrny K Jr, Bouda M, Kohoutkova L et al. A clinical study to assess the effect of heparin in dialyser rinsing solutions. Int J Artif Organs 1997; 20: 112-118
17. Klingel R, Schaefer M, Schwarting A et al. Comparative analysis of procoagulatory activity of haemodialysis, haemofiltration and haemodiafiltration with a polysulfone membrane (APS) and with different modes of enoxaparin anticoagulation. Nephrol Dial Transplant 2004; 19: 164-170
18. Gritters-van den Oever M, Grooteman MP, Bartels PCM et al. Post-dilution haemodiafiltration and low-flux haemodialysis have dissimilar effects on platelets: a side study of CONTRAST. Nephrol Dial Transplant 2009; 24: 3461-3468
19. Sirolli V, Ballone E, Di Stante S et al. Cell activation and cellular-cellular interactions during hemodialysis: Effect of dialy-zer membrane. Int J Artif Organs 2002; 25: 529-537
20. Kuragano T, Kuno T, Takahashi Y et al. Comparison of the effects of cellulose triacetate and polysulfone membrane on GPIIb/IIIa and platelet activation. Blood Purif 2003; 21: 176-182
21. Gritters M, Borgdorff P, Grooteman MP et al. Platelet activation in clinical haemodialysis: LMWH as a major contributor to bio-incompatibility? Nephrol Dial Transplant 2008; 23: 2911-2917
22. Moal V, Brunet P, Dou L et al. Impaired expression of glyco-proteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 2003; 18: 1834-1841
23. Bartels PCM, Heine SF, Schoorl M et al. A new parameter for screening on platelet dysfunction in subjects treated with haemodialysis. Ned Tijdschr Klin Chem 1998; 23: 73
24. Thekkedath UR, Chirananthavat T, Leypoldt JK et al. Elevated fibrinogen fragment levels in uremic plasma inhibit platelet function and expression of glycoprotein IIb-IIIa. Am J Hematol 2006; 81: 915-926
25. Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocy-topenia. Kidney Int 2012; 82: 147-157
26. Cardigan RA, Mackie IJ, Machin SJ. Hemostatic-endothelial interactions: A potential anticoagulant role of the endo-thelium in the pulmonary circulation during cardic surgery. J Cardiothorac Vasc Anesth 1997; 11: 329-336
27. Chuang YC, Chen JB, Yang LC et al. Significance of platelet activation in vascular access survival of haemodialysis patients. Nephrol Dial Transplant 2003; 18: 947-954
28. Wasse H, Gillen DL, Ball AM et al. Risk factors for upper gastrointestinal bleeding among end-stage renal disease patients. Kidney Int 2003; 64: 1455-1461
29. Knoll GA, Wells PS, Young D et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005; 16: 1108-1114